In its report, the Authority noted that the studies of Myers et al., 2006 and Becker et al., 2009 showed an effect of monacolin K in SYLVAN BIO red yeast rice on blood LDL-cholesterol concentrations at doses of about 9 and 10 mg per day respectively. As stated in the opinion, this is in the range of the doses used in the two human intervention studies (Heber et al., 1999; Lin et al., 2005) which were evaluated by the Authority to set conditions of use of 10 mg monacolin K per day for a claim on monacolin K from red yeast rice preparations in general and maintenance of normal blood LDL-cholesterol concentrations (EFSA NDA Panel, 2011). The Authority also noted that when setting conditions of use, it takes into account and weighs the totality of the available scientific evidence. In this specific case, the Authority took into account the evidence provided by two human intervention studies (Heber et al., 1999; Lin et al., 2005) at doses of around 7,5 and 11,5 mg/day monacolin K, as well as the lowest dose of lovastatin (pure monacolin K) which has been shown consistently to reduce LDL-cholesterol concentrations in the target population (i.e. 10 mg/day). The Authority concluded that the comments received did not change its conclusions and reconfirmed its opinion.
Recital 26, Regulation (EU) 2024/2063
In forcesince 30 Jul 2024